The Hepatitis C Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Hepatitis C Market:
https://www.thebusinessresearchcompany.com/report/hepatitis-c-global-market-report
According to The Business Research Company’s Hepatitis C Global Market Report 2024, The hepatitis c market size has grown rapidly in recent years. It will grow from $59.58 billion in 2023 to $68.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to blood transfusion practices, injection drug use, limited treatment options, development of direct-acting antivirals (daas).
The hepatitis c market size is expected to see rapid growth in the next few years. It will grow to $117.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to global elimination efforts, improved testing and screening, rising healthcare spending, integration of telemedicine, emerging therapeutic combinations. Major trends in the forecast period include accessible and affordable treatment, focus on high-risk groups, improved drug formulations, collaborative efforts and partnerships, telehealth and digital solutions.
An increase in viral infections is expected to propel the growth of the hepatitis C market going forward. Viral infections refer to infections caused by a virus in the body. Hepatitis C treatment reduces viral infection by eradicating viral infection and restoring immune response in hepatitis C patients after viral clearance. For instance, according to the European Centre for Disease Prevention and Control, a Sweden-based government agency, in 2021, 14,560 cases of hepatitis C were reported in 29 European Economic Area (EEA) member states, which is an increase compared to 13,914 cases reported in the previous year. Therefore, an increase in viral infections is driving the hepatitis C market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12582&type=smp
The hepatitis c market covered in this report is segmented –
1) By Type: Chronic Hepatitis C, Acute Hepatitis C, Other Types
2) By Treatment: Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Other Treatments
3) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
4) By Distribution Channel: Hospital And Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Research Institutes, Home Care Settings
Top Major Players
Pfizer Inc.
Johnson & Johnson Services Inc.
F. Hoffman La Roche Ltd.
Merck & Co. Inc.
AbbVie Inc.
Advances in diagnostic technologies for hepatitis C are a key trend gaining popularity in the hepatitis C market. Major companies operating in the hepatitis C market are adopting new technologies to sustain their position in the market. For instance, in July 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, launched Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The hepatitis C virus (HCV) antigen and antibody status can now be determined independently and simultaneously from a single human plasma or serum sample using the immunoassay Elecsys HCV Duo. The test can identify patients recovering or exhibiting symptoms of a chronic infection that may result in other diseases, such as liver cancer and early-stage conditions.
The hepatitis c market report table of contents includes:
1. Executive Summary
2. Hepatitis C Market Characteristics
3. Hepatitis C Market Trends And Strategies
4. Hepatitis C Market - Macro Economic Scenario
5. Global Hepatitis C Market Size and Growth
........................
32. Global Hepatitis C Market Competitive Benchmarking
33. Global Hepatitis C Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Hepatitis C Market
35. Hepatitis C Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Global Hepatitis C Treatment Market: OverviewThe demand within the global market for hepatitis C treatment has been rising on account of advancements in the field of healthcare and medicine.
Several new treatment lines for the treatment of hepatitis C have been developed over the past decade.
Henceforth, the global market for hepatitis C treatment has accumulated voluminous revenues over the past decade.
Healthcare professionals have emphasised on the need to develop new treatment lines for hepatitis C. There is no doubt about the fact that the global hepatitis C treatment would accumulate humongous revenues in the years to come.
The emergence of new vendors in the global hepatitis C treatment has also aided market growth.Strong expertise with attention to detail makes our market research reports stand apart, Request a Report sample @https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=65471The global hepatitis C treatment has been segmented on the basis of the following parameters: treatment type, end user, and region.
Furthermore, new entries have invested in the global hepatitis C treatment market which has in turn given an impetus to the growth of the global market.Request COVID Analysis on Hepatitis C Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=65471Global Hepatitis C Treatment Market: Regional OutlookOn the basis of geography, the global market for hepatitis C treatment can be segmented into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific.
Demand for Hepatitis C Treatment Expected to Remain High in North America during 2016-2024
According to a recent study conducted by RRI, the global market for hepatitis C treatment is expected to expand at a CAGR of over 13% during the forecast period (2016-2024). By the end of 2016, market is anticipated to stand at US$ 26.6 and is estimated to surpass US$ 71 Billion by 2024.
Factors such as higher per capita healthcare expenditure worldwide and growing prevalence of hepatitis C infections in countries such as U.S. and Canada is expected to drive the global market for global hepatitis C treatment during the forecast period. Moreover, increasing awareness campaigns by private NGPOs and encouraging government initiatives to limit infection is also supporting the market growth. On the other hand, expensive drugs for hepatitis C treatment and lack of awareness about hepatitis C infection amongst the people in developing regions across the globe may inhibit the growth of the market during the forecast period.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114958/Hepatitis-C-Treatment-Market
On the basis of drugs, the global market for hepatitis C treatment has been segmented into HCV NS5A inhibitors, HCV protease inhibitors, interferon & antiviral, HCV polymerase inhibitors, and combination therapy. Amongst these, combination therapy is expected to be the largest, accounting for the highest share of the market. The segment is expected to expand at a CAGR of over 13% during 2016-2024.
On the basis distribution channel, the market has been segmented into online pharmacies, hospital pharmacies and retail pharmacies. Hospital pharmacy is expected to be the most dominant segment during the forecast period. By 2024, the segment is anticipated to account for over 43% share of the market in terms of revenue. Due to increasing occurrence of hospitalization and improved services and accessibility, demand for the segment is expected to grow higher in the near future.
On the other hand, the online pharmacies segment is anticipated to witness the highest CAGR over the forecast period. The growth of the segment is due to ample stock of hepatitis C treatment drugs with added discount offered by online drug pharmacies.
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114958/Hepatitis-C-Treatment-Market
On the basis of region, North America is expected to be the leading market for hepatitis C treatment, estimated to account for 45% share by the end of 2016. Whereas, the market in Asia Pacific is anticipated to expand at an overwhelming CAGR of over 14%. By 2016, Europe is estimated to contribute over 19% share to the global market for hepatitis C treatment. The market in Latin America is expected to witness a sound growth, which was estimated at US$ 2,915.8 Million in 2015 and is expected to surpass US$ 3,311 by 2016 year end. In 2015, the market in the Middle East and Africa (MEA) region stood at US$ 1,792.5 Million and is anticipated to cross US$ 1,988 Million by the end of 2016.
Vendor News
Key participants operating in the global market for hepatitis C treatment include F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and Kadmon Holdings, Inc. Most of these companies are actively focusing on partnering with healthcare solutions and service providers in order to offer better patient treatment and enhance operational efficiency.
Summary: The global market for hepatitis C treatment expected to grow at a pronounced rate.
Research Report Insights
42 joseph street,
Portcarling P0B 1J0,
Muskoka, Ontario, Canada
T: +1-631-721-4201
Email: [email protected]
Web Site: http://www.researchreportinsights.com
Phone - (+91) 7875758555
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114958/Hepatitis-C-Treatment-Market
“Global Hepatitis C Diagnosis and Treatment Market Research Report – Forecast to 2025” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2025.Global Hepatitis C Diagnosis and Treatment Market – OverviewHepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc.
According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives.
Furthermore, Hepatitis B and C are major contributing factors to liver cancer.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/1569According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.
Global Hepatitis C Diagnosis and Treatment Market-Competitive AnalysisHoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.October, 2013 – Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline.
According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.October, 2013 – Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD).
This report focuses on top manufacturers in Global Market. The Global DNA Testing/Diagnostics Market is anticipated to grow at a staggering CAGR in the forthcoming period.
Diagnostic tests are the basis of a successful healthcare system that enables vital information about patients and healthcare providers necessary to land into right decisions.
The drivers for DNA Testing/Diagnostics market include demand for personalized medicine applications for chronic disorders is likely to propel the DNA Testing/Diagnostics market growth. By technology, the DNA diagnostics market comprises in-situ hybridization, microarray, PCR, mass spectrometry and sequencing technology.
